Eurotransplant just published its factsheet. We kindly invite you to download this two page document with essential key information about Eurotransplant.
In 2000, Slovenia joined the Eurotransplant cooperation. To celebrate this 20th anniversary a professional symposium takes place today in the University Medical Center of Ljubljana, Slovenia. Key professionals in donor and transplant medicine in Slovenia will present achievements and think about the future challenges. Peter Branger, general director of Eurotransplant, has shared his views on fruitful cooperation between Slovenia and Eurotransplant.
Benefits of cooperation
Through 20 years of excellent collaboration the cooperation enabled better treatment outcomes for many Slovenian patients, who benefited from a larger donor pool within Eurotransplant. Direct positive impact was seen in the rise of national donation rates, while waiting lists for transplantation became shorter. Combined transplantations became possible as well.
Eurotransplant congratulates Slovenia on this 20th anniversary and looks forward to continue the successful cooperation in the future.
The provisional monthly statistics of December have been published.
LEIDEN (the Netherlands) – January 14, 2020 – Eurotransplant announces that preliminary annual figures 2019 on waiting list, donation, organ allocation for transplantation as well as the number of transplanted patients in the Eurotransplant region, are now available online.
Last year 6,973 organs (2018: 7,401) from 2,041 deceased donors (2018: 2,159) were used for transplantation for patients on the waiting list of Eurotransplant. This is a decrease of 5,5 % compared to 2018. The year 2020 started with 13,985 patients (2019: 14,129) registered on the active waiting list for an organ transplant.
In 2019, 21.4 % (2018, 23.6%) of organs were exchanged between the Eurotransplant member states. Thanks to this international exchange, a suitable donor organ could be found for many patients in the different Eurotransplant member states. This specifically applies to patients in special groups such as children, patients with acute organ failure (high urgency patients) as well as patients with a complex medical background (highly immunized patients). For these special patient groups the chance of receiving a suitable organ in time is significantly higher, due to the cooperation within Eurotransplant.
Furthermore, organ exchange between eight countries within Eurotransplant ensures that donor organs that would remain unused in one country become available for patients in other countries because there is no suitable recipient for this organ in this country.
Statistics per country
Please find detailed tables and charts with key figures on waiting list, donation and transplantation, specified by organ, by country and by year (including 2019) in the online statistics library.
Please be aware that slight deviations in the numbers can occur when comparing Eurotransplant figures with figures provided by national organizations in Eurotransplant member states. This may be caused by differences in calculation (e.g. counting double lung transplant as one or two transplants) and times of registration (counting based on time of donation or time of transplantation). Eurotransplant only reports on utilized donors (deceased donors of which at least one organ was used for transplantation). In every table in the Eurotransplant statistics library, the precise method of counting is mentioned.
More information about figures
Questions about the annual figures 2019 can be sent to firstname.lastname@example.org
After almost five years of discussion, adaptations and preparations, the new Eurotransplant governance structure will come into effect in January 2020.
Responsible stewardship of a foundation requires a periodically review of the governance structure: to ascertain that it still meets current obligations and best practices in non-profit governance. In 2015, the Board of Eurotransplant initiated a review of its corporate and governance structure in close cooperation with representatives of the different Eurotransplant member states. The Board’s goal is to create a governance structure and process that is responsive to Eurotransplant’s members wants and needs, serves centers and health care professionals efficiently and meets current and future challenges.
Based on this consultation the Board has developed the following new governance structure for Eurotransplant:
- A Board of Management, consisting of a General Director and a Medical Director. Almost all management tasks and responsibilities will be contributed to the Board of Management. This Board is responsible for realizing the objectives as defined in Eurotransplant’s vision and mission, for the strategy with its associated risk profile and for the social aspects of running a business that are relevant to the foundation. The new structure thus allows an efficient, effective and transparent communication and decision-making process which will be beneficial to the internal organization.
- A Supervisory Board that will supervise the Board of Management. The Supervisory Board is responsible for the appointed of the members of the Board of Management, evaluates their functioning and decides on their competence to lead the Leiden Office. The function of the Supervisory Board consists partly of supervision beforehand, namely the granting of approval, and partly afterwards. These competences have been further specified in the new Articles of Association.
- Two Councils will be set up which have an advisory role towards the Board of Management. In the Council of Administration, representatives of the National Competent Authorities will be involved in advising on matters of finance and ICT.
- The Council of Medicine and Science will consist of representatives of the national transplant societies, an ethicist and representatives from the transplant programs (members A who will be elected by the Assembly as laid down in the Articles of Association). The Council of Medicine and Science prepares and advices on recommendations regarding allocation and allocation development.
Certain issues, such as the accession of new member states, the annual budget and changes to the Articles of Association, require approval of the ministries of Health of the Eurotransplant member states.
The provisional monthly statistics of November have been published.
It is with great sadness that we announce the passing away of Eurotransplant’s vice president and long-time board member Prof. Dr. Xavier Rogiers. Xavier died last Wednesday night, November 20, surrounded by his family. After being diagnosed with malignancy last summer, and having undergone intensive treatment, we all hoped that he was on the way to good recovery. But alas, it was not to be.
To do justice to the many-sided person and the impressive career of Xavier Rogiers would take many a page. But summing up some of the highlights may give a good impression of his numerous achievements. Born and raised in the West-Flemish town of Ieper, he had his medical education in Leuven (Belgium). His training in surgery and obstetrics culminated in a doctorate degree with magna cum laude distinction (1982). Additional surgical fellowships in hepatobiliary and transplant surgery brought him to Paris, Glasgow, London and Chicago, to name but a few places. During these years Xavier showed himself to be a true pioneer in the development of hepatobiliary surgery and in particular liver transplantation. He made important contributions to living-donor liver transplantation, and split-liver transplantation. After his fellowship in Chicago (1989-1990), he came to the prominent liver transplant center of Hamburg-Eppendorf (Germany), where he became medical director of the Transplant Center and was appointed professor ordinarius at the Hamburg University (2001). In 2006 Xavier Rogiers returned to his native Belgium to hold the chair of Transplantation Surgery at the University of Ghent and become Head of the Transplant Center at the University Medical Center (UZ Gent). In that busy and responsible position, he still found time to contribute to the first full facial transplant (2012), and the first uterus transplant (2018) in Belgium. Besides his passion for cutting-edge transplant surgery and research, Xavier throughout his career demonstrated a dedication to education and also played a prominent role in international professional cooperation, as is witnessed by his leadership in ELITA, ESOT and ESA, as well as the European Regional Association of the International Hepato-Pancreatic-Biliary Association (E-AHPBA).
In his capacity as board member and vice president of Eurotransplant, Xavier made invaluable contributions to setting quality standards in liver and intestinal transplantation and allocation (ELIAC), developing the all-important data registry, and lately, having intense debate and negotiation on the new Eurotransplant governance structure. His presence in these meetings, quiet but always attentive, with a focus on constructive debate and realistic solutions, earned him the admiration and support of many, both in and outside Eurotransplant. We will remember him as a good friend, a wise advisor, a tireless supporter of cooperation, earnest and unpretentious in character and with a big heart and humanity towards all who had the privilege to work with him.
With Xavier’s demise we have lost a dear friend: he will be sorely missed by many.
Bruno Meiser, President Eurotransplant
Peter Branger, General Director
The provisional monthly statistics of October have been published.